Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2009
12/30/2009WO2009130422A3 N-acylthiourea and n-acylurea inhibitors of the hedgehog protein signalling pathway
12/30/2009WO2009106748A3 Derivatives of n-phenyl-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof
12/30/2009WO2009062118A3 Modulation of protein trafficking
12/30/2009WO2008155588A8 Sulfonyl-quinoline derivatives
12/30/2009WO2008140335A3 Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
12/30/2009EP2138498A1 Substituted tricyclic derivatives against neurodegenerative diseases
12/30/2009EP2138495A1 Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives
12/30/2009EP2138494A1 Substituted alkyl pyrimidin-4-one derivatives
12/30/2009EP2138493A1 Substituted pyrimidone derivatives
12/30/2009EP2138492A1 Substituted pyrimidin-4-one derivatives
12/30/2009EP2138488A1 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
12/30/2009EP2138487A1 Substituted morpholine and thiomorpholine derivatives for the treatment of bipolar disorders
12/30/2009EP2138485A1 Substituted N-Oxide pyrazine derivatives
12/30/2009EP2138177A1 Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments
12/30/2009EP2138176A1 Method of treating cognitive impairment
12/30/2009EP2138175A2 Formulations comprising valsartan for treating diabetes or microalbuminuria
12/30/2009EP2138174A1 Pharmaceutical composition in the form of a sublingual tablet consisting of a non-steroidal anti-inflammatory agent and an opiate analgesic for pain management
12/30/2009EP2138173A1 Pharmaceutical compositions comprising aminoadamantane derivatives
12/30/2009EP2138170A2 Prevention and Treatment of Oxidative Stress Disorders by compounds which elevate intracellular levels of glutathione or Phase II Detoxification Enzymes
12/30/2009EP2137193A2 Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof
12/30/2009EP2137192A1 Derivatives of galantamine as pro-drugs for the treatment of human brain diseases
12/30/2009EP2137167A1 Dihydro-benzo[b][1,4]diazepin-2-one sulfonamide derivatives
12/30/2009EP2137156A1 Orally bioavailable prodrugs of (+)-3-hydroxymorphinan for parkinson's disease prevention or treatment
12/30/2009EP2137155A1 Quinoline derivatives, pharmaceutical compositions comprising them, and their use in treating central nervous system and peripheral diseases
12/30/2009EP2137146A1 Crystalline forms of atorvastatin 4-(nitrooxy) butyl ester
12/30/2009EP2136816A2 Oleyl phosphocholine
12/30/2009EP2136638A1 Modified release formulations of (6r)-4,5,6,7-tetrahydro-n6-propyl-2,6-benzothiazole-diamine and methods of using the same
12/30/2009EP2049525B1 N-(aminoheteroaryl)-1h-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof
12/30/2009EP1558577B1 Substituted 4-phenyl-piperidin-amides as tachykinin antagonists and serotonin reptake inhibitors
12/30/2009EP1523541B1 A process for decreasing environmental pollutants in an oil or a fat, a volatile environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
12/30/2009EP1448565B1 ADENOSINE A2a RECEPTOR ANTAGONISTS
12/30/2009EP1126882B1 Stable preparations with hyperforin
12/30/2009CN101613321A Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
12/30/2009CN101612402A Interferon antagonist and use of Flt3L interferon
12/30/2009CN100575497C Preparation of microbial oil containing polyunsaturated fatty acids
12/30/2009CN100575345C Pyridone derivative having affinity for cannabinoid 2-type receptor
12/30/2009CN100575334C Substituted 2-dialkylaminoalkylbiphenyl derivatives
12/30/2009CN100574785C Compound Chinese traditional medicine for treating neuropathic pain
12/30/2009CN100574782C Application of aqueous solution containing nicotine in preparing medicine for quit smoking
12/30/2009CN100574758C Compound for treating ischemic related disease
12/30/2009CN100574755C Hot melt transcutaneous therapeutic system for administering D2 accelerator
12/30/2009CN100574750C Rapidly-disintegrating formulation for releasing active ingredients
12/30/2009CA2847644A1 Glycerophospholipids for the improvement of cognitive functions
12/30/2009CA2766282A1 Inhibitors of carnitin-palmitoyl-transferase-1 for the treatment and prevention of disorders caused by delipidation of neural tissue
12/30/2009CA2729275A1 5- and 6-membered heterocyclic compounds
12/30/2009CA2729259A1 1,2-disubstituted heterocyclic compounds
12/30/2009CA2729227A1 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
12/30/2009CA2729220A1 Di-substituted phenyl compounds
12/30/2009CA2729115A1 Substituted triazinone derivatives
12/30/2009CA2729034A1 Use
12/30/2009CA2728730A1 Novel tetramethyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
12/30/2009CA2728728A1 Substituted tricyclic derivatives
12/30/2009CA2728696A1 Substituted pyrimidin-4-one derivatives
12/30/2009CA2728695A1 Substituted alkyl pyrimidin-4-one derivatives
12/30/2009CA2728694A1 Substituted pyrimidone derivatives
12/30/2009CA2728693A1 Substituted pyrimido [2, 1-a] isoquinolin-4-one derivatives
12/30/2009CA2728680A1 Substituted n-oxide pyrazine derivatives
12/30/2009CA2728652A1 Use of cyclolignans for the treatment of a hyperactive immune system
12/30/2009CA2728646A1 Serine glycerophospholipid conjugates and their use in the improvement of cognitive functions
12/30/2009CA2728283A1 Isoquinolinone derivatives as nk3 antagonists
12/30/2009CA2728137A1 Substituted isoquinolines and isoquinolinones as rho kinase inhibitors
12/30/2009CA2728123A1 Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives
12/30/2009CA2728089A1 Therapeutic agent for spinal canal stenosis
12/30/2009CA2727737A1 Materials and methods for suppressing and/or treating neurofibroma and related tumors
12/30/2009CA2727573A1 Diaryl compounds and uses thereof
12/30/2009CA2727444A1 Triazolo [4,5-d] pyramidine derivatives and their use as purine receptor antagonists
12/30/2009CA2727340A1 Carboxylic acid compound
12/30/2009CA2726834A1 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds
12/30/2009CA2726291A1 Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders
12/29/2009US7638630 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors
12/29/2009US7638607 Urocortin proteins and uses thereof
12/29/2009US7638601 Transient receptor potential channel TRPM8 and its use
12/29/2009US7638551 Amino alcohol compounds or phosphonic acid derivatives thereof
12/29/2009US7638546 Imidazolyl derivatives
12/29/2009US7638538 4-chloro-N-({5-[({2-[(2-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}ethyl)amino]-2-oxoethyl}amino)sulfonyl]thien-2-yl}methyl)benzamide; inhibitor of jun N-terminal kinase 2 and 33 inhibitor; autoimmune disorders
12/29/2009US7638534 Use of indazole derivatives for the treatment of neuropathic pain
12/29/2009US7638532 exo-3-(3 ,4-Dichloro-phcnoxy)-8-aza-bicyclo[3.2.1]oct-6-ene; antidepressants, psychological disorders
12/29/2009US7638528 Drug delivery agent containing an anticarcinogenic agent such as mitoxanthrone, doxorubicin, methotrexate etc. covalently linked to a compound via an ester, amido or carabamte linkage to the S, O or amino group of the compound
12/29/2009US7638523 e.g. tert-butyl 2-(4-(2-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-5-yl)-2-fluorobenzamido)acetate; C-kit kinase receptor or stem cell factor inhibitors; asthma allergic sinusitis and rhinitis, atopic and allergic dermatitis, allergic contact rheumatoid arthritis, multiple sclerosis, lupus etc.
12/29/2009US7638518 3-(Benzimidazol-2-yl)pyrazole derivatives; inhibitors of ATP and protein kinase interactions; diabetes, rheumatoid arthritis, Crohn's disease, septic shock, cachexia, pancreatitis, Alzheimer's disease, Parkinson's disease; antimetastasis, anticarcinogenic, antitumor, antidepressant, antiallergen agents
12/29/2009US7638516 Agent for therapeutic treatment of optic nerve diseases and the like
12/29/2009US7638511 Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
12/29/2009US7638510 Racemic mixtures; treating drug abuse, drug dependence
12/29/2009US7638494 G-type peptides to ameliorate atherosclerosis
12/29/2009US7638492 Using programmed death-1 (PD-1) protein as evaluative tool to identify modulators for treatment and prevention of nervous system, autoimmune, cell proliferative and allergic disorders
12/29/2009US7638330 Method of promoting the differentiation of staminal cells
12/29/2009US7638328 Method for efficient transfer of human blastocyst-derived stem cells (hBS cells) from a feeder-supported to a feeder-free culture system, long-term propagation of hBS cells under feeder-free conditions and use of cultured hBS cells for applications in myocardial regeneration
12/29/2009US7638327 polypeptides related to a receptor to BAFF (a B-cell activating factor belonging to the Tumor Necrosis Factor family, which is associated with expression of B-cells and immunoglobulins); treatment of cancers, lymphomas, autoimmune diseases related to B-cells
12/29/2009US7638283 Amyloid β protein (globular assembly and uses thereof)
12/29/2009US7638141 Generating multipotent cells from sstem cells isolated from residual cord blood; tissue engineering and regenerative medicine
12/29/2009CA2478799C Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
12/29/2009CA2466490C Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
12/29/2009CA2465877C Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase
12/29/2009CA2465349C Transdermal drug for the treatment of neural paralysis and dysfunction
12/29/2009CA2464768C Method and composition for potentiating an opiate analgesic
12/29/2009CA2447521C Delivery of antihistamines through an inhalation route
12/29/2009CA2443019C Kappa-opiate agonists for the treatment of bladder diseases
12/29/2009CA2428511C Novel uses of combined 5-ht1a agonists and serotonin reuptake inhibitors
12/29/2009CA2428133C Indolylmaleimide derivatives as protein kinase c inhibitors
12/29/2009CA2425215C Compositions and methods for enhancing paracellular permeability across epithelial and endothelial barriers
1 ... 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 ... 1833